Population pharmacokinetics of intramuscular artesunate in african children with severe malaria: Implications for a practical dosing regimen

Clinical Pharmacology and Therapeutics

Volumn 93, Issue 5, 2013, Pages 443-450

  Hendriksen, I C E ^a,b   Mtove, G ^c   Kent, A ^d   Gesase, S ^c   Reyburn, H ^e   Lemnge, M M ^c   Lindegardh, N ^a,b   Day, N P J ^a,b   Von Seidlein, L ^f   White, N J ^a,b   Dondorp, A M ^a,b   Tarning, J ^a,b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (Tanzania)

^d Joint Malaria Programme   (Tanzania)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ARTEMETHER PLUS BENFLUMETOL; ARTESUNATE; DIHYDROARTEMISININ; PYRIMETHAMINE PLUS SULFADOXINE; QUININE;

AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CHILD; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; FOLLOW UP; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MAXIMUM PLASMA CONCENTRATION; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TANZANIA; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANTIMALARIALS; ARTEMISININS; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFANT; INJECTIONS, INTRAMUSCULAR; MALARIA, FALCIPARUM; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; SEVERITY OF ILLNESS INDEX; TANZANIA; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 84876666742     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.26     Document Type: Article

References (44)

1. World Health Organization. World Malaria Report 2008. 〈http://www.who.int/malaria/publications/atoz/9789241563697/en/index. html〉 (2008). Accessed 10 October 2011.
2. Marsh, K. et al. Indicators of life-threatening malaria in African children. N. Engl. J. Med. 332, 1399-1404 (1995).
3. Waller, D. et al. Clinical features and outcome of severe malaria in Gambian children. Clin. Infect. Dis. 21, 577-587 (1995).
4. World Health Organization. Guidelines for the treatment of malaria 2010, second edition-Rev.1. 〈http://www.who.int/malaria/publications/atoz/ 9789241547925/en/index.html〉 2011 Accessed 4 May 2011.
5. Dondorp, A., Nosten, F., Stepniewska, K., Day, N. & White, N. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 366, 717-725 (2005).
6. Dondorp, A.M. et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 376, 1647-1657 (2010).
7. Ter Kuile, F., White, N.J., Holloway, P., Pasvol, G. & Krishna, S. Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria. Exp. Parasitol. 76, 85-95 (1993).
8. White, N.J. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob. Agents Chemother. 41, 1413-1422 (1997).
9. Nealon, C. et al. Intramuscular bioavailability and clinical efcacy of artesunate in gabonese children with severe malaria. Antimicrob. Agents Chemother. 46, 3933-3939 (2002).
10. Hien, T.T. et al. Comparative pharmacokinetics of intramuscular artesunate and artemether in patients with severe falciparum malaria. Antimicrob. Agents Chemother. 48, 4234-4239 (2004).
11. Navaratnam, V., Mansor, S.M., Sit, N.W., Grace, J., Li, Q. & Olliaro, P. Pharmacokinetics of artemisinin-type compounds. Clin. Pharmacokinet. 39, 255-270 (2000).
12. Davis, T.M. et al. Pharmacokinetics and pharmacodynamics of intravenous artesunate in severe falciparum malaria. Antimicrob. Agents Chemother. 45, 181-186 (2001).
13. Simpson, J.A. et al. Population pharmacokinetics of artesunate and dihydroartemisinin following intra-rectal dosing of artesunate in malaria patients. PLoS Med. 3, e444 (2006).
14. Batty, K.T., Ilett, K.F. & Davis, T.M. Protein binding and alpha: beta anomer ratio of dihydroartemisinin in vivo. Br. J. Clin. Pharmacol. 57, 529-533 (2004).
15. Newton, P.N. et al. The pharmacokinetics of intravenous artesunate in adults with severe falciparum malaria. Eur. J. Clin. Pharmacol. 62, 1003-1009 (2006).
16. Li, G.Q., Guo, X.B., Jin, R., Wang, Z.C., Jian, H.X. & Li, Z.y. Clinical studies on treatment of cerebral malaria with qinghaosu and its derivatives. J. Tradit. Chin. Med. 2, 125-130 (1982).
17. Bartelink, I.H., Rademaker, C.M., Schobben, A.F. & van den Anker, J.N. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin. Pharmacokinet. 45, 1077-1097 (2006).
18. Barnes, K.I., Little, F., Smith, P.J., Evans, A., Watkins, W.M. & White, N.J. Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin. Pharmacol. Ther. 80, 582-596 (2006).
19. Tarning, J. et al. Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clin. Pharmacol. Ther. 91, 497-505 (2012).
20. Kremsner, P.G. et al. A simplifed intravenous artesunate regimen for severe malaria. J. Infect. Dis. 205, 312-319 (2012).
21. Karunajeewa, H.A. et al. Artesunate suppositories versus intramuscular artemether for treatment of severe malaria in children in Papua New Guinea. Antimicrob. Agents Chemother. 50, 968-974 (2006).
22. Bethell, D.B. et al. Pharmacokinetics of oral artesunate in children with moderately severe Plasmodium falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 91, 195-198 (1997).
23. Tarning, J. et al. Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and non-pregnant women with uncomplicated malaria. Antimicrob Agents Chemother 56:1997-2007 (2012).
24. Tran, T.H. et al. A controlled trial of artemether or quinine in V ietnamese adults with severe falciparum malaria. N. Engl. J. Med. 335, 76-83 (1996).
25. van Hensbroek, M.B. et al. A trial of artemether or quinine in children with cerebral malaria. N. Engl. J. Med. 335, 69-75 (1996).
26. Artemether-Quinine Meta-analysis Study Group. A meta-analysis using individual patient data of trials comparing artemether with quinine in the treatment of severe falciparum malaria. Trans R Soc Trop Med Hyg 95, 637-650 (2001).
27. Murphy, S.A. et al. The disposition of intramuscular artemether in children with cerebral malaria; a preliminary study. Trans. R. Soc. Trop. Med. Hyg. 91, 331-334 (1997).
28. Phu, N.H. et al. Randomized controlled trial of artesunate or artemether in Vietnamese adults with severe falciparum malaria. Malar. J. 9, 97 (2010).
29. Ilett, K.F. et al. The pharmacokinetic properties of intramuscular artesunate and rectal dihydroartemisinin in uncomplicated falciparum malaria. Br. J. Clin. Pharmacol. 53, 23-30 (2002).
30. Morris, C.A., Duparc, S., Borghini-Fuhrer, I., Jung, D., Shin, C.S. & Fleckenstein, L. Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malar. J. 10, 263 (2011).
31. Byakika-Kibwika, P. et al. Pharmacokinetics and pharmacodynamics of intravenous artesunate during severe malaria treatment in Ugandan adults. Malar. J. 11, 132 (2012).
32. Karunajeewa, H.A. et al. Disposition of artesunate and dihydroartemisinin after administration of artesunate suppositories in children from Papua New Guinea with uncomplicated malaria. Antimicrob. Agents Chemother. 48, 2966-2972 (2004).
33. Stepniewska, K. et al. Population pharmacokinetics of artesunate and amodiaquine in African children. Malar. J. 8, 200 (2009).
34. Lindegardh, N. et al. Quantifcation of dihydroartemisinin, artesunate and artemisinin in human blood: overcoming the technical challenge of protecting the peroxide bridge. Bioanalysis 3, 1613-1624 (2011).
35. Snow, R.W. et al. Relation between severe malaria morbidity in children and level of Plasmodium falciparum transmission in Africa. Lancet 349, 1650-1654 (1997).
36. Billig, E.M., O'Meara, W.P., Riley, E.M. & McKenzie, F.E. Developmental allometry and paediatric malaria. Malar J 11, 64 (2012).
37. Bethell, D. et al. Dose-dependent risk of neutropenia after 7-day courses of artesunate monotherapy in Cambodian patients with acute Plasmodium falciparum malaria. Clin. Infect. Dis. 51, e105-e114 (2010).
38. Batty, K.T. et al. A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria. Br. J. Clin. Pharmacol. 45, 123-129 (1998).
39. McGready, R. et al. Artesunate/dihydroartemisinin pharmacokinetics in acute falciparum malaria in pregnancy: absorption, bioavailability, disposition and disease efects. Br. J. Clin. Pharmacol. 73, 467-477 (2012).
40. Maitland, K. et al. Mortality after fuid bolus in African children with severe infection. N. Engl. J. Med. 364, 2483-2495 (2011).
41. Hendriksen, I.C. et al. Diagnosing severe falciparum malaria in parasitaemic African children: a prospective evaluation of plasma PfHRP2 measurement. PLoS Med. 9, e1001297 (2012).
42. Lindegardh, N. et al. Major pitfalls in the measurement of artemisinin derivatives in plasma in clinical studies. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 876, 54-60 (2008).
43. Hanpithakpong, W. et al. A liquid chromatographic-tandem mass spectrometric method for determination of artesunate and its metabolite dihydroartemisinin in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 876, 61-68 (2008).
44. Bergstrand, M., Hooker, A.C., Wallin, J.E. & Karlsson, M.O. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-efects models. AAPS J. 13, 143-151 (2011).